Business Context and Reporting Period
This Form 8-K is filed by Oculus Innovative Sciences, Inc. (not Sonoma Pharmaceuticals, Inc., as noted in the metadata) for the reporting period of March 13, 2015. The filing details the entry into material definitive agreements regarding the sale of the company's stake in Ruthigen, Inc., triggered by Ruthigen's announced merger with Pulmatrix, Inc.
Key Financial Metrics and Transaction Values
The filing does not provide standard financial statements (revenue, profit, cash flow, or margins). It focuses on specific transaction values related to the divestiture of Ruthigen shares:
- Total Ruthigen Shares Held: 2,000,000 shares.
- Transaction 1 (Follow-up Agreement): Sale of 1,650,000 shares at $2.75 per share for an aggregate price of $4,537,500.
- Transaction 2 (Securities Purchase Agreement): Sale of 350,000 shares at $2.75 per share for an aggregate price of $962,500.
- Total Aggregated Sale Price: $5,500,000 for all 2,000,000 shares.
- Potential Contingent Payment: If the pre-merger Ruthigen business is sold for gross consideration exceeding $10 million, Oculus is entitled to 10% of such gross consideration.
Material Changes and Agreements
On March 13, 2015, Oculus entered into several agreements altering its relationship with Ruthigen and its investors:
- Share Sales: Oculus agreed to sell its entire 2,000,000 share stake in Ruthigen to investors. The sale of 1,650,000 shares is expected to close at the time of the Ruthigen merger (prior to August 13, 2015, extendable by 60 days). The sale of the remaining 350,000 shares is expected to close within 10 business days of March 13, 2015.
- License and Supply Agreement: Oculus waived Ruthigen's obligation to develop and commercialize products until the earlier of August 31, 2016, or one year after the merger. The definition of "Field" was amended to mean surgical irrigation drug product indications, and the manufacturing option for Ruthigen was deleted.
- Shared Services Termination: The shared services agreement between Oculus and Ruthigen was mutually terminated.
- Non-Compete: Hoji Alimi, a former officer of Oculus and director of Ruthigen, agreed to a one-year non-compete clause effective March 13, 2015.
Outlook, Risks, and Contingencies
Outlook and Conditions: The sale of the 1,650,000 shares is contingent on the Ruthigen merger closing. If the merger does not close by August 13, 2015 (or the extended date), there is no obligation to purchase the shares. Oculus retains voting rights for specific share blocks until the merger closes.
Risks and Forward-Looking Statements: The filing includes standard disclaimers that forward-looking statements are based on current expectations and involve risks. Actual outcomes may differ materially due to factors discussed in the company's Form 10-K. The filing explicitly states it does not constitute an offer to sell securities in jurisdictions where such an offer would be unlawful.
Investor Verification Checklist
- Verify the closing status of the Ruthigen and Pulmatrix merger, as the $4.5 million portion of the share sale is contingent on this event.
- Confirm the timeline for the closing of the 350,000 share sale (expected within 10 business days of March 13, 2015).
- Review the amended License and Supply Agreement to understand the scope of the "Field" (surgical irrigation) and the removal of Ruthigen's manufacturing options.
- Monitor for any potential sale of the pre-merger Ruthigen business that could trigger the 10% gross consideration payment to Oculus.
- Check the full text of Exhibits 10.1 through 10.4 for complete legal terms regarding the securities purchase agreements.